Microsynth (founded in 1989) is a leading European company in nucleic acid synthesis & analysis. The main activities are divided into these business areas: DNA/RNA synthesis - DNA/RNA analysis and sequencing - Contract research/outsourcing
Products, services, technology
Oligonucleotides (primers for R&D, ASOs for drug discovery, probes for diagnostics)
DNA sequencing (Sanger & NGS); Isolation and Assaying (PCR, qPCR, digital PCR, genotyping etc.)
Contract research (GLP/GMP-compliant assay development, biological testing, CRISPR gene editing analysis etc.)
We help our customers deliver diagnostic results for human health, develop therapeutics faster, and gain vital insights into basic research. We also provide a good work/life balance environment and act sustainably as an employer.
The way in which we successfully balance continuous corporate growth with sustainable management – something we’ve done ever since we were founded in 1989. And we are particularly proud of our ecological behavior and commitment.
Inside Microsynth: the two founders, Tobias and Denise Schmidheini, who have a very modest and eco-friendly lifestyle, still work hard for the company. Outside: Jean Paul and Martine Clozel from Idorsia (could have retired long ago), but they keep going to fight diseases, not to get rich.
What are the core strengths of your current team and what skills are you looking forward to integrate in the future?
The scientific expertise in nucleic acid synthesis and analysis, process automation, and the ability to deliver products and services of the highest quality. We are committed to expand our regulatory capabilities to further support our customers in the therapeutic and diagnostic fields.
They would (hopefully!) say we develop and supply nucleic acid-based syntheses and analyses for pharma, biotech, and academia. And in doing so, we promote scientific progress in this field.
Our brand is very well known in Switzerland. We’re almost immediately associated with oligos and Sanger sequencing. But few people know that we’re also a small, powerful CRO. We hope the Swiss Biotech Association will provide us with a platform to promote the contract research part of our business.
Decision makers who need high-quality assays and biological tests in the development or commercialization phase of their drugs. Whenever GxP-compliant genetic assays are needed for identity, stability, or potency testing, we hope they’ll think of Microsynth and get in touch.